FitLife Brands
FitLife Brands' revenue rose 26.4% to $82 million in fiscal 2025. Its operating margin was 12.3%, down from 20.4% a year earlier. Free cash flow was $7 million, down 22.9%. The diluted share count rose 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What FitLife Brands does
FitLife Brands sells nutritional supplements and wellness products under a group of brands it has mostly bought over time. They include sports nutrition and weight loss products sold under NDS Nutrition, PMD Sports and iSatori; MusclePharm sports nutrition; Dr. Tobias supplements and skincare sold mainly on Amazon; and Irwin Naturals, a supplement maker it bought out of bankruptcy in August 2025 for $42.5 million, mostly paid with new bank loans.
It makes money by selling these products through several channels. Its NDS products go mainly to about 600 franchised GNC stores in the United States and to franchise stores abroad, and since the launch of its Metis Nutrition line it also sells through more than 1,300 company-owned GNC stores. Online sales matter most: about 49% of its 2025 sales came through Amazon's U.S. marketplace. Irwin sells mainly to mass retailers such as CVS, Walmart, Walgreens and Costco Canada, and to health food stores. It relies on a few outside suppliers and manufacturers to make its products.
The company is based in Omaha, Nebraska. It had 81 full-time employees at the end of 2025, up from 39 a year earlier, mainly because of the Irwin deal.
Its biggest risks, as it describes them
- Relying on Amazon's U.S. marketplace for a large share of sales, where any limit on its selling would hurt.
- Depending on GNC and a few other large partners for a big portion of its sales.
- Debt taken on for acquisitions, and loan terms that limit what it can do.
- Relying on a small number of outside suppliers and manufacturers.
- Bad publicity about its products or ingredients, whose health benefits rest on limited clinical studies.
Income statement
From fiscal 2016 to 2025, earnings per share grew 32.5% a year and net income 35.8% a year, as new shares raised the share count by 20% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 10 | 13 | 1 | 4 | 2 |
| Debt incl. finance leases | 0 | 0 | 20 | 13 | — |
| Net debt (negative means net cash) | −10 | −13 | 19 | 9 | — |
| Net debt to EBITDA | −1.6x | −2.3x | 2.5x | 0.7x | — |
| Debt to equity | 0.0x | 0.0x | 0.7x | 0.4x | — |
| Interest coverage | — | — | 7.4x | 9.6x | 5.4x |
| Current ratio | 4.4x | 5.4x | 1.4x | 1.6x | 1.5x |
| Quick ratio | 2.8x | 3.3x | 0.5x | 0.6x | 0.5x |
Cash flow
Projections
Project FitLife Brands' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What FitLife Brands says to expect
- Fourth quarter 2026 onward: annual operating expense
The initiative, which was substantially completed by the end of the third quarter, is anticipated to decrease the Company’s annual operating expense by approximately $1.2 million annually beginning in the fourth quarter of 2026.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $71,989 of FitLife Brands shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Shannon K. PappasDirector | Bought | 1,000 | $10.25 | $10,250 | Form 4 |
| Apr 10, 2026 | Grant Robert DawsonDirector | Bought | 3,000 | $9.98 | $29,940 | Form 4 |
| Apr 10, 2026 | Matthew LingenbrinkDirector | Bought | 3,000 | $9.76 | $29,280 | Form 4 |
| Jan 15, 2026 | Seth YakatanDirector | Bought plan | 164 | $15.36 | $2,519 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 6 of 9 | — |
| Rule of 40 | 90.8% | 37.2% | 35.4% |
| Altman Z'' | 2.23 | 4.28 | 2.44 |
| Accruals ratio | 2.7% | −1.1% | −1.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 9 | 6 of 9 | — |
Compare
Put FitLife Brands side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| FitLife Brands | FY25 | 26.4% | 12.3% | 9.1% | — | — | — | |
| Solesence | FY25 | 18.6% | 4.2% | — | — | — | — | Compare |
| Mannatech | FY25 | −8.3% | −0.4% | −4.0% | — | −4.1x | 2 | Compare |
| Niagen Bioscience | FY25 | 29.9% | 12.6% | — | — | −3.8x | 6 | Compare |
| Cronos Group | FY25 | 24.6% | −11.9% | 0.1% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 25 | 18 | 17 | 20 | 22 | 28 | 29 | 53 | 64 | 82 |
| Revenue growth | 41.2% | −29.7% | −4.1% | 14.2% | 11.5% | 28.4% | 3.2% | 83.0% | 22.3% | 26.4% |
| Gross profit | 10 | 5 | 7 | 8 | 10 | 12 | 12 | 21 | 28 | 32 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 0 | −9 | 1 | 2 | 4 | 6 | 6 | 8 | 13 | 10 |
| Net income | 0 | 0 | 0 | 3 | 9 | 5 | 4 | 5 | 9 | 6 |
| Diluted EPS (US$) | 0.05 | −1.16 | 0.05 | 0.29 | 0.97 | 0.56 | 0.45 | 0.54 | 0.91 | 0.63 |
| Diluted shares (millions) | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Cash flow | ||||||||||
| Cash from operations | 0 | 1 | 0 | 2 | 6 | 4 | 4 | 4 | 10 | 7 |
| Capital expenditure | 0 | 0 | 0 | — | — | — | 0 | 0 | 0 | 0 |
| Free cash flow | 0 | 0 | 0 | — | — | — | 4 | 4 | 10 | 7 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 1 | 1 | 0 | 0 | 6 | 10 | 13 | 1 | 4 | 2 |
| Debt incl. finance leases | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 13 | — |
| Total assets | 15 | 7 | 6 | 6 | 17 | 22 | 26 | 55 | 58 | 106 |
| Total liabilities | 5 | 6 | 4 | 3 | 5 | 4 | 4 | 28 | 22 | 63 |
| Shareholders' equity | 1 | 1 | 2 | 3 | 12 | 17 | 21 | 27 | 36 | 44 |
| Margins and ratios | ||||||||||
| Gross margin | 39.8% | 28.6% | 39.5% | 40.9% | 43.9% | 44.8% | 41.8% | 40.7% | 43.6% | 38.6% |
| Operating margin | 1.9% | −50.3% | 3.8% | 12.8% | 20.0% | 22.3% | 19.8% | 14.3% | 20.4% | 12.3% |
| Net margin | 1.4% | 2.9% | 3.0% | 13.4% | 40.6% | 19.4% | 15.4% | 10.1% | 13.9% | 7.8% |
| Free cash flow margin | 0.1% | 2.7% | 1.5% | — | — | — | 14.3% | 7.8% | 14.9% | 9.1% |
| Rule of 40 (growth + FCF margin) | 41.3% | −27.0% | −2.5% | — | — | — | 17.5% | 90.8% | 37.2% | 35.4% |
| Return on capital | 8.9% | — | 66.0% | 106.3% | 104.2% | 77.4% | 55.7% | 21.1% | 21.9% | — |
| Return on equity | 6.7% | 55.8% | 33.5% | 100.3% | 118.1% | 37.0% | 22.9% | 21.9% | 28.4% | 15.9% |
| Return on assets | 2.2% | 4.6% | 7.7% | 42.3% | 77.9% | 28.4% | 18.8% | 13.1% | 15.8% | 7.7% |
| Net debt to EBITDA | −0.7x | — | −0.4x | −0.1x | −1.4x | −1.6x | −2.3x | 2.5x | 0.7x | — |